Executive function impairment and memory impairment

Consider the following scenario: Your patient has suffered from schizophrenia for two decades and has received classic dopaminergic treatments since the onset of illness. The latest research supporting use of the glutamatergic model has not been tried on your patient, and there is an opportunity for your patient to enter clinical trials utilizing glutamate-based treatments. Your patient suffers significant executive function impairment and memory impairment. Do you recommend participation in the clinical trial? Why or why not?
Use at least one scholarly source other than your textbook to connect your response to national guidelines and evidence-based research in support of your ideas.